ASLN   $0.6  -14.27% Market Closed

Aslan Pharmaceuticals Ltd
Total Cash 18.40M
totalCashPerShare 0.039
EBITDA -34.89M
Total Debt 26.67M
quickRatio 0.938
currentRatio 1.05
Total Revenue 12.00M
debtToEquity
Revenue/Share 5.514
ROA -0.53692
ROE
grossProfits
freeCashflow
operatingCashflow
earningsGrowth
revenueGrowth
grossMargins 1.0
ebitdaMargins -2.90779
operatingMargins -2.9103
profitMargins -2.9189003
enterpriseValue 288.33M
forwardPE -0.031914897
floatShares 410.33M
sharesOutstanding 2.83M
sharesShort 38.32K
sharesShortPriorMonth 37.17K
dateShortInterest
sharesPercentSharesOut 0.01%
heldPercentInsiders 0.00%
heldPercentInstitutions 0.13%
Short Ratio help_outline 1.85%
shortPercentOfFloat 0.01%
impliedSharesOutstanding
bookValue -7.698
Price To Book help_outline
earningsQuarterlyGrowth
netIncomeToCommon -35.03M
trailingEps -16.00%
forwardEps -18.80%
enterpriseToEbitda -8.26
lastDividendValue
lastDividendDate
currentQuarterEstimate -3.6 2Q 2024
institutionsCount 23
lastUpdated Aug. 19, 2024, 12:11 a.m.